Osteosarcoma MRI
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammadmain Rezazadehsaatlou[2].
Osteosarcoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Osteosarcoma MRI On the Web |
American Roentgen Ray Society Images of Osteosarcoma MRI |
Overview
On MRI, osteosarcoma is characterized by intermediate intensity of soft tissue and low signal intensity of ossified components on T1. High signal intensity of soft tissue and low signal intensity of ossified components on T2. Considerable contrast enhancement of solid components on T1 contrast.
MRI
- MRI is proving essential in accurate local staging and assessment for limb sparing resection, particularly for evaluation of intraosseous tumor extension and soft-tissue involvement.
- Assessment of the growth plate is also essential as up to 75-88% of metaphyseal tumors do cross the growth plate into the epiphysis.
- MRI is used to:[1][2][3][4][5][6]
- Show how far a bone tumor has grown inside a bone.
- Show how much a bone tumor has grown outside the bone.
- Observe if a tumor has grown into blood vessels, nerves, bone marrow or other nearby tissues or structures.
- Determine if the tumor has developed in one or more sites within the same bone (skip metastases).
- Plan for possible surgery.
On MRI, signal characteristics of osteosarcoma include:
- T1:
- Soft tissue, non-mineralized component: intermediate signal intensity.
- Mineralized/ossified components: low signal intensity.
- Peritumoral edema: intermediate signal intensity.
- Scattered regions of hemorrhage will have variable signal.
- T2:
- T1 C+ (Gd):
- Solid components show considerable enhancement.
-
Coronal T1
-
Coronal T1 C+ fat sat
-
Axial T2
-
Axial T2 fat sat
-
Axial T1
-
Axial T1 C+ fat sat
- The following table illustrates the findings on MRI for the subtypes of osteosarcoma:
Subtype | MRI findings |
---|---|
|
|
|
|
|
|
|
|
|
|
References
- ↑ Sue M, Oda T, Sasaki Y, Kameta A, Okada Y, Ogura I (2017). "Osteosarcoma of the Mandible: a Case Report with CT, MRI and Scintigraphy". Chin J Dent Res. 20 (3): 169–172. doi:10.3290/j.cjdr.a38772. PMID 28808701.
- ↑ Kubo T, Furuta T, Johan MP, Adachi N, Ochi M (September 2016). "Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis". Skeletal Radiol. 45 (9): 1235–42. doi:10.1007/s00256-016-2410-y. PMID 27229874.
- ↑ Kasalak Ö, Overbosch J, Glaudemans A, Boellaard R, Jutte PC, Kwee TC (April 2018). "Primary tumor volume measurements in Ewing sarcoma: MRI inter- and intraobserver variability and comparison with FDG-PET". Acta Oncol. 57 (4): 534–540. doi:10.1080/0284186X.2017.1398411. PMID 29117758. Vancouver style error: initials (help)
- ↑ Degnan AJ, Chung CY, Shah AJ (2018). "Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors". Clin Imaging. 47: 9–13. doi:10.1016/j.clinimag.2017.08.003. PMID 28806574.
- ↑ Uchiyama Y, Matsumoto K, Murakami S, Kanesaki T, Matsumoto A, Kishino M, Furukawa S (2014). "MRI in a case of osteosarcoma in the temporomandibular joint". Dentomaxillofac Radiol. 43 (2): 20130280. doi:10.1259/dmfr.20130280. PMC 4064616. PMID 24247589.
- ↑ Wakabayashi H, Saito J, Taki J, Hashimoto N, Tsuchiya H, Gabata T, Kinuya S (January 2016). "Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy". Skeletal Radiol. 45 (1): 87–95. doi:10.1007/s00256-015-2250-1. PMID 26385785.